Circulating suPAR in two cohorts of primary FSGS

Changli Wei, Howard Trachtman, Jing Li, Chuanhui Dong, Aaron L. Friedman, Jennifer J. Gassman, June L. McMahan, Milena Radeva, Karsten M. Heil, Agnes Trautmann, Ali Anarat, Sevinc Emre, Gian M. Ghiggeri, Fatih Ozaltin, Dieter Haffner, Debbie S. Gipson, Frederick Kaskel, Dagmar Christiane Fischer, Franz Schaefer, Jochen Reiser

Research output: Contribution to journalArticlepeer-review


Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to primary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease. Here, we analyzed circulating suPAR levels in two cohorts of children and adults with biopsy-proven primary FSGS: 70 patients from the North America-based FSGS clinical trial (CT) and 94 patients from PodoNet, the Europe-based consortium studying steroid-resistant nephrotic syndrome. Circulating suPAR levels were elevated in 84.3% and 55.3% of patients with FSGS patients in the CT and PodoNet cohorts, respectively, compared with 6% of controls (P

Original languageEnglish
Pages (from-to)2051-2059
Number of pages9
JournalJournal of the American Society of Nephrology
Issue number12
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Circulating suPAR in two cohorts of primary FSGS'. Together they form a unique fingerprint.

Cite this